Your session is about to expire
← Back to Search
Anti-metabolites
Methotrexate + Dipyridamole for Ovarian Cancer
Phase 2
Waitlist Available
Research Sponsored by Ottawa Regional Cancer Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Clinical or radiographic evidence of advanced, predominantly peritoneal disease on physical exam, CT or MRI scan, exploratory laparotomy, or peritoneal cytology or by elevated CA-125 (above 35 units in Ottawa Civic or General Hospitals) required
No second malignancy other than basal cell carcinoma of the skin
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well methotrexate and dipyridamole work together in treating patients with ovarian cancer.
Who is the study for?
This trial is for adults over 18 with advanced ovarian cancer that didn't respond to or came back within a year after platinum-based chemotherapy. They must have had surgery considered, show evidence of mainly peritoneal disease, and have a life expectancy of more than 2 months. Key blood, liver, and kidney function tests must meet specific levels. Those with other cancers besides basal cell skin carcinoma or who need certain drugs that interact with the trial medications can't join.Check my eligibility
What is being tested?
The study is testing if combining methotrexate (MTX) with dipyridamole (DP) is effective in treating patients whose ovarian cancer has returned or resisted previous cisplatin-based treatments. It's a Phase II trial aiming to see if this drug combo can better stop tumor cells from growing by using different mechanisms.See study design
What are the potential side effects?
Methotrexate may cause side effects like mouth sores, low blood counts leading to infection risk, liver issues, and kidney problems. Dipyridamole might lead to bleeding complications due to its antiplatelet effect and could also cause headaches or gastrointestinal discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My tests show advanced cancer mainly in the abdomen.
Select...
I have no cancer other than possibly skin cancer.
Select...
My kidney function tests are within normal limits.
Select...
My liver function tests are within normal limits.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Ottawa Regional Cancer CentreLead Sponsor
6 Previous Clinical Trials
482 Total Patients Enrolled
Rakesh Goel, MD, FRCPCStudy ChairOttawa Regional Cancer Centre
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have recovered from side effects of my previous cancer treatments.I am not currently receiving chemotherapy.My tests show advanced cancer mainly in the abdomen.My ovarian cancer is advanced and didn't respond to platinum-based treatments within a year.I am not taking any blood thinners or medications that widen blood vessels.Debulking surgery was considered after my last chemotherapy.My cancer can be measured or observed, regardless of its size.I have not had radiation therapy in my abdomen or pelvic area.I have no cancer other than possibly skin cancer.My kidney function tests are within normal limits.I am not taking drugs that interact with DP or MTX, including blood thinners or chemotherapy.I have received platinum-based chemotherapy before.I am not receiving radiotherapy to my abdomen.My liver function tests are within normal limits.My main cancer symptoms or threats come from the peritoneal area.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any unfilled appointments for this clinical trial?
"According to the listing on clinicaltrials.gov, this trial is not recruiting patients at this time. The study was originally posted on 7/1/1991 and last updated 9/16/2013. Although this particular trial has completed patient recruitment, there are 702 other trials that are still looking for participants."
Answered by AI
Has this medication received FDA clearance?
"This experimental treatment received a safety score of 2 because, while there is data supporting that it is safe, there is no evidence yet that it is effective."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger